WallStSmart

Accenture plc (ACN)vsHumana Inc (HUM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Humana Inc generates 90% more annual revenue ($137.20B vs $72.11B). ACN leads profitability with a 10.6% profit margin vs 0.8%. ACN appears more attractively valued with a PEG of 1.26. ACN earns a higher WallStSmart Score of 62/100 (C+).

ACN

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 8.0Quality: 5.3
Piotroski: 3/9Altman Z: 2.79

HUM

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 4.5Value: 7.3Quality: 7.5
Piotroski: 4/9Altman Z: 4.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACNUndervalued (+36.1%)

Margin of Safety

+36.1%

Fair Value

$280.38

Current Price

$174.57

$105.81 discount

UndervaluedFair: $280.38Overvalued
HUMUndervalued (+81.0%)

Margin of Safety

+81.0%

Fair Value

$1141.73

Current Price

$246.33

$895.40 discount

UndervaluedFair: $1141.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACN4 strengths · Avg: 8.5/10
Market CapQuality
$110.85B9/10

Large-cap with strong market position

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

P/E RatioValuation
14.8x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$3.67B8/10

Generating 3.7B in free cash flow

HUM4 strengths · Avg: 8.5/10
Altman Z-ScoreHealth
4.3710/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.5%8/10

Revenue surging 23.5% year-over-year

Free Cash FlowQuality
$1.13B8/10

Generating 1.1B in free cash flow

Areas to Watch

ACN2 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

HUM4 concerns · Avg: 2.8/10
Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
4.7%3/10

Operating margin of 4.7%

EPS GrowthGrowth
-4.6%2/10

Earnings declined 4.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACN

The strongest argument for ACN centers on Market Cap, Return on Equity, P/E Ratio. PEG of 1.26 suggests the stock is reasonably priced for its growth.

Bull Case : HUM

The strongest argument for HUM centers on Altman Z-Score, Price/Book, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bear Case : ACN

The primary concerns for ACN are EPS Growth, Piotroski F-Score.

Bear Case : HUM

The primary concerns for HUM are Return on Equity, Profit Margin, Operating Margin. Thin 0.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ACN profiles as a value stock while HUM is a growth play — different risk/reward profiles.

ACN carries more volatility with a beta of 1.07 — expect wider price swings.

HUM is growing revenue faster at 23.5% — sustainability is the question.

ACN generates stronger free cash flow (3.7B), providing more financial flexibility.

Bottom Line

ACN scores higher overall (62/100 vs 59/100). HUM offers better value entry with a 81.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accenture plc

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Accenture plc is an Irish-domiciled multinational company that provides consulting and processing services. It has been incorporated in Dublin, Ireland since 2009.

Humana Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.

Visit Website →

Want to dig deeper into these stocks?